Last reviewed 2026-05-14 · How we verify

OCS (prednisone/prednisolone)

OCS (prednisone/prednisolone) is a Glucocorticoid Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Asthma, Rheumatoid arthritis, Multiple sclerosis.

Prednisone and prednisolone are synthetic glucocorticoids that mimic the effects of cortisol in the body, reducing inflammation and suppressing the immune system.

OCS (oral corticosteroids, prednisone/prednisolone) is a foundational immunosuppressive therapy used across multiple therapeutic areas including asthma, autoimmune disorders, and myasthenia gravis. As a small-molecule glucocorticoid receptor agonist, OCS exerts broad anti-inflammatory and immunosuppressive effects by binding the cytoplasmic glucocorticoid receptor, translocating to the nucleus, and modulating transcription of pro-inflammatory cytokines and adhesion molecules. While not a novel drug class, OCS remains clinically significant as a steroid-sparing agent in combination regimens—particularly evident in GSK-sponsored Phase 3 trials evaluating mepolizumab (an IL-5 antagonist) for severe asthma and hypereosinophilic syndrome, where OCS dose reduction is a primary endpoint. The commercial importance of OCS lies in its role as a comparator and baseline therapy in modern biologic development; recent pipeline activity includes Alexion's Phase 4 study of OCS tapering in generalized myasthenia gravis, reflecting ongoing optimization of steroid-sparing strategies. Generic prednisone/prednisolone dominates the market with minimal differentiation; GSK's involvement centers on clinical validation of OCS reduction through biologic combination therapy rather than proprietary OCS formulations.

At a glance

Mechanism of action

Glucocorticoids like prednisone and prednisolone work by binding to glucocorticoid receptors in cells, which then translocate to the nucleus and alter gene expression to reduce inflammation and immune responses. This can be beneficial in treating conditions like asthma, rheumatoid arthritis, and certain types of cancer, but can also have significant side effects due to the suppression of the immune system.

Approved indications

• Asthma
• Rheumatoid arthritis
• Multiple sclerosis
• Crohn's disease
• Ulcerative colitis
• Cancer (e.g. leukemia, lymphoma)

Common side effects

• Weight gain
• Increased blood pressure
• Osteoporosis
• Glaucoma
• Cataracts
• Hypokalemia

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• OCS (prednisone/prednisolone) CI brief — competitive landscape report
• OCS (prednisone/prednisolone) updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI

Frequently asked questions about OCS (prednisone/prednisolone)

Related

• Drug class: All Glucocorticoid drugs
• Target: All drugs targeting Glucocorticoid receptor
• Manufacturer: GlaxoSmithKline — full pipeline
• Therapeutic area: All drugs in Immunology, Rheumatology, Pulmonology
• Indication: Drugs for Asthma
• Indication: Drugs for Rheumatoid arthritis
• Indication: Drugs for Multiple sclerosis
• Compare: OCS (prednisone/prednisolone) vs similar drugs
• Pricing: OCS (prednisone/prednisolone) cost, discount & access